Patents by Inventor Hannah L. POWERS

Hannah L. POWERS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF
    Publication number: 20240246939
    Abstract: Provided herein are compounds of formula (I?): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y2, Y3, L1, L2, X1, X2, X3, X4, X5, Q1, R1, R2, Rk, Rm, and Rn are as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I?). Also provided herein are methods of inhibiting GYS1 and methods of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.
    Type: Application
    Filed: September 8, 2023
    Publication date: July 25, 2024
    Inventors: David John MORGANS, JR., Kevin MELLEM, Hannah L. POWERS, Patrick Sang Tae LEE, Walter WON, Christopher Joseph SINZ
  • Compounds and Their Use for Treatment of Hemoglobinopathies
    Publication number: 20240208937
    Abstract: Disclosed herein are compounds and methods for the prevention and/or treatment of hemoglobinopathies. Also provided herein are such compounds for use in such methods. Also disclosed herein are pharmaceutical compositions comprising such compounds for use in such methods of preventing or treating hemoglobinopathies.
    Type: Application
    Filed: November 3, 2023
    Publication date: June 27, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Thomas J. Cummins, Daniel K. Cashion, Jacob T. Edwards, Antonia Lopez-Girona, Joshua Hansen, Scott Arne Johnson, Mark A. Nagy, Kevin M. Oberg, Hannah L. Powers, Giorgio Tamo
  • Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof
    Patent number: 11814367
    Abstract: Provided herein are compounds of formula (I?): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y2, Y3, L1, L2, X1, X2, X3, X4, X5, Q1, R1, R2, Rk, Rm, and Rn are as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I?). Also provided herein are methods of inhibiting GYS1 and methods of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: November 14, 2023
    Assignee: MAZE THERAPEUTICS, INC.
    Inventors: David John Morgans, Jr., Kevin Mellem, Hannah L. Powers, Patrick Sang Tae Lee, Walter Won, Christopher Joseph Sinz
  • INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF
    Publication number: 20230104740
    Abstract: Provided herein are compounds of formula (I?): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y2, Y3, L1, L2, X1, X2, X3, X4, X5, Q1, R1, R2, Rk, Rm, and Rn are as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I?). Also provided herein are methods of inhibiting GYS1 and methods of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.
    Type: Application
    Filed: March 14, 2022
    Publication date: April 6, 2023
    Inventors: David John MORGANS, JR., Kevin MELLEM, Hannah L. POWERS, Patrick Sang Tae LEE, Walter WON, Christopher Joseph SINZ